search icon
      blog search icon

      BeiGene Stock Price History and Quote Analysis: Insights for Investors

      BeiGene, Ltd.



      1.88 (1.03%)

      At Close: 4:00 PM

      BeiGene Stock Price Graph

      • 1D
      • 5D
      • 1M
      • 3M
      • 6M
      • 1Y
      • YTD
      • All

      BeiGene Stock Price Today

      BeiGene, Ltd. (BGNE) stock rallied over 1.03% intraday to trade at $184.84 a share on NASDAQ. The stock opened with a loss of -4.53% at $174.68 and touched an intraday high of $176.95, rising 1.03% against the last close of $182.96. The BeiGene, Ltd. in stock market went to a low of $169.85 during the session.

      BeiGene Stock Snapshot


      Prev. Close

      17.61 Billion

      Market Cap


      Day Low




      Number of Shares


      Day High


      P/E ratio


      EPS (TTM)


      Cash Flow per Share


      Free Float in %


      Book Value



      BeiGene Stock Price History Chart


      Contact Details

      55 Cambridge Parkway
      Cambridge, MA 02142


      Contact #:781-801-1800

      Company Information



      Sales or Revenue$2.2 Billion

      5Y Sales Change74.50%

      Fiscal Year EndsDec. 2022



      About Company

      BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.


      Frequently Asked Questions


      What is the current BeiGene, Ltd. (BGNE) stock price?

      BeiGene, Ltd. (NASDAQ: BGNE) stock price is $184.84 in the last trading session. During the trading session, BGNE stock reached the peak price of $176.95 while $169.85 was the lowest point it dropped to. The percentage change in BGNE stock occurred in the recent session was 1.03% while the dollar amount for the price change in BGNE stock was $1.88.


      BGNE's industry and sector of operation?

      The NASDAQ listed BGNE is part of Biotechnology industry that operates in the broader Healthcare sector. BeiGene, Ltd. , a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide.


      Who are the executives of BGNE?

      Ms. Stacey Jurchison
      Executive Director of Corporation Affairs
      Dr. Yan Qi
      Senior Vice President & Head of Public Affairs - Greater China
      Dr. Xiaobin Wu Ph.D.
      Pres, Chief Operating Officer & GM of China
      Dr. Xiaodong Wang Ph.D.
      Co-Founder, Chairman of Scientific Advisory Board & Non-Executive Director


      How BGNE did perform over past 52-week?

      BGNE's closing price is 1.21% higher than its 52-week low of $156.56 where as its distance from 52-week high of $280.62 is -0.07%.


      How many employees does BGNE have?

      Number of BGNE employees currently stands at N/A. BGNE operates from 55 Cambridge Parkway, Cambridge, MA 02142, US.


      Link for BGNE official website?

      Official Website of BGNE is:


      How do I contact BGNE?

      BGNE could be contacted at phone #781-801-1800 and can also be accessed through its website. BGNE operates from 55 Cambridge Parkway, Cambridge, MA 02142, US.


      How many shares of BGNE are traded daily?

      BGNE stock volume for the day was 104100.00 shares. The average number of BGNE shares traded daily for last 3 months was 214.23 Thousands.


      What is the market cap of BGNE currently?

      The market value of BGNE currently stands at $17.61 Billion with its latest stock price at $184.84 and N/A of its shares outstanding.